NCT06584032 is a Phase 3 clinical trial of fruquintinib in Advanced Endometrial Cancer, sponsored by Hutchmed.

Who is sponsoring NCT06584032?

NCT06584032 is sponsored by Hutchmed.

What drugs are being tested in NCT06584032?

Interventions in NCT06584032: fruquintinib, sintilimab, paclitaxel, doxorubicin.

What condition does NCT06584032 study?

NCT06584032 studies Advanced Endometrial Cancer.

Is NCT06584032 still recruiting?

NCT06584032 is currently recruiting now. Last updated 7 January 2025.

Last reviewed 2025-01-07 · How we verify

NCT06584032

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Recruiting now Phase 3 Last updated 7 January 2025

What this trial tests

Phase 3 trial testing fruquintinib in Advanced Endometrial Cancer in 412 participants. Currently enrolling.

Timeline

12 December 2024

Primary endpoint
8 January 2029

9 June 2029

Quick facts

Lead sponsor	Hutchmed
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	412
Start date	12 December 2024
Primary completion	8 January 2029
Estimated completion	9 June 2029
Sites	17 locations across China

Drugs / interventions tested

fruquintinib
sintilimab — full drug profile →
paclitaxel — full drug profile →
doxorubicin (doxorubicin) — full drug profile →

Conditions studied

Advanced Endometrial Cancer — all drugs for Advanced Endometrial Cancer →

Sponsor

Hutchmed — full company profile →

Who can join

Adults 18 to 75, female only, with Advanced Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial.
Wu X, Wang J, Wang D, Li G, et al · · 2025 · PMID 41423492 · DOI 10.1038/s41467-025-67375-3

Verify or expand the search:

Other trials of fruquintinib

Trials testing the same drug.

NCT07270991 — Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma · Phase 3 · recruiting
NCT05993702 — TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer · unknown
NCT05941325 — A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of · Phase 2 · recruiting
NCT04179084 — Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal · Phase 2 · unknown

Other recruiting trials for Advanced Endometrial Cancer

Currently open trials in the same condition.

NCT06758557 — A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor · Phase 1, PHASE2 · recruiting

Other Hutchmed trials

Trials by the same sponsor.

NCT07409428 — A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL · Phase 3 · recruiting
NCT07396584 — HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor · Phase 1, PHASE2 · recruiting
NCT07228247 — A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07348133 — Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets · Phase 1 · completed
NCT07331194 — Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06584032 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hutchmed
Last refreshed: 7 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06584032.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing